Study of Cryoablation and Nirogacestat for Desmoid Tumor

Recruiting

I'm Interested

Trial ID: NCT05949099

Purpose

The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.

Official Title

Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor

Stanford Investigator(s)

Nam Quoc Bui
Nam Quoc Bui

Clinical Assistant Professor, Medicine - Oncology

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)

Pejman Ghanouni, MD, PhD
Pejman Ghanouni, MD, PhD

Associate Professor of Radiology (General Radiology) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology

Eligibility


Inclusion Criteria:

   1. Histologically-confirmed diagnosis of desmoid tumor (DT) that is progressing (by
   RECIST criteria over the past 12 months) or symptomatic (as defined by change in pain
   regimen or impairment of activities of daily living (ADLs), or at investigator
   discretion). Note: Must have diagnosis of desmoid tumor on pathology report.

   2. Desmoid tumor is 50 to <75% cryoablatable.

   Tumors that are 50 to <75% (volume) ablatable in a single session are characterized
   by:

      1. Proximity (< 1 cm) to critical structures, such as nerves, vessels, bowel, or
      skin, at risk of injury during ablation, despite hydrodissection

      2. Large size ( > 100 mL)

      3. Complex shape, such that parts of the tumor cannot be reached from a single
      approach or subject position

      4. Thin, infiltrative components, where ablation of that portion would damage more
      normal anatomy than tumor (e.g., tumor extending along a fascial plane between
      muscles, such that ablation would damage more muscle than tumor volume)

   3. If participant is currently being treated with any therapy for the treatment of DT,
   this must be completed at least 28 days (or 5 half-lives, whichever is shorter) prior
   to first dose of study treatment. All toxicities from prior therapy must be resolved
   to ≤ Grade 1 or clinical baseline.

   4. Participants who are receiving chronic nonsteroidal anti-inflammatory drugs (NSAIDs)
   as treatment for conditions other than DT must be on a stable dose for at least 28
   days prior to first dose of study treatment.

   5. Age ≥ 18 years.

   6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at
   screening.

   7. Participant has adequate organ and bone marrow function as defined by the following
   screening laboratory values:

      1. Absolute neutrophil count ≥ 1500 cells/μL;

      2. Platelets ≥ 100,000μL;

      3. Hemoglobin ≥ 9 g/dL;

      4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (isolated bilirubin > 1.5 ×
      ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%);

      5. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic
      transaminase)/alanine aminotransferase (ALT) (serum glutamic pyruvate
      transaminase) ≤ 2 × ULN; and

      6. Serum creatinine ≤ 1.5 × ULN or if creatinine > 1.5 × ULN then calculated
      creatinine clearance must be ≥ 60 mL/min (using the Cockcroft-Gault formula)

   8. Women of childbearing potential must have a negative serum pregnancy test at
   screening.

   9. Participant can swallow tablets.

10. Participant able to have MRI.

11. Ability to understand and the willingness to personally sign the written IRB-approved
   informed consent document.

12. Contraceptive use by men or women should be consistent with the standard that will be
   used at Stanford regarding the methods of contraception for those participating in
   clinical studies.

      1. Male participants: Male participants are eligible to participate if they agree to
      the following during the treatment period and for at least 90 days after the last
      dose of study treatment:

      • Refrain from donating or preserving sperm;

      PLUS either:

         - Be abstinent from sexual intercourse as their preferred and usual lifestyle
         (abstinent on a long-term and persistent basis) and agree to remain
         abstinent; OR

         - Must agree to use a male condom when having sexual intercourse with women of
         childbearing potential (WOCBP). An additional form of contraception as
         described in Appendix G should also be used by the female partner, if she is
         of childbearing potential.

      Postmenopausal state (not of childbearing potential) is defined as no menses for
      12 months without an alternative medical cause.

      2. Female participants: A female participant is eligible to participate if she is
      not pregnant or breastfeeding, and at least one of the following conditions
      applies:

         - Is not of childbearing potential (not WOCBP). OR

         - Is of childbearing potential but is abstinent or using 1 highly effective
         contraceptive method, as described in Appendix H during the treatment period
         and for at least 6 months after the last dose of active study treatment. (A
         second method of contraception is required if the participant is using
         hormonal contraception, as coadministration with nirogacestat may alter the
         plasma concentrations of hormonal contraceptives resulting in reduced
         efficacy)

         - The investigator is responsible for review of medical history, menstrual
         history, and recent sexual activity to decrease the risk for inclusion of a
         woman with an early undetected pregnancy.

Exclusion Criteria:

   1. Participant previously received or is currently receiving therapy with GS inhibitors
   or anti-Notch antibody therapy.

   2. Participant is currently using any treatment for DT including tyrosine kinase
   inhibitors (TKIs), NSAIDS (chronic daily use - except as in inclusion criterion 3) or
   any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to
   the first dose of study treatment.

   3. Participant is currently using or anticipates using food or drugs that are known
   strong or moderate cytochrome P450 3A4 (CYP3A4) inhibitors, or strong CYP3a inducers
   within 14 days prior to the first dose of study treatment.

   4. Participant has known hypersensitivity to the active substance or to any of the
   excipients of nirogacestat.

   5. Participant with active or chronic infection at the time of informed consent and
   during the screening period.

   6. Participant has known malabsorption syndrome or preexisting gastrointestinal condition
   that may impair absorption of nirogacestat (e.g., gastric bypass, lap band, or other
   gastric procedures that would alter absorption); delivery of nirogacestat via
   nasogastric tube or gastrostomy tube is not allowed.

   7. History of other high-grade malignancy ≤ 2 years previous. Exceptions include prior or
   concurrent malignancy whose natural history or treatment does not have the potential
   to interfere with the safety or efficacy assessment of the investigational regimen;
   adequately treated basal cell or squamous cell skin cancer; or adequately treated,
   with curative intent, cancer from which the subject is currently in complete remission
   per study Principal Investigator's (PI's) judgment. Specific situations can be
   discussed with study PI.

   8. Participant has experienced any of the following within 6 months of signing informed
   consent:

      - Clinically significant cardiac disease (New York Heart Association Class III or
      IV);

      - Myocardial infarction

      - Severe / unstable angina

      - Coronary / peripheral artery bypass graft

      - Symptomatic congestive heart failure

      - Cerebrovascular accident

      - Transient ischemic attack

      - Symptomatic pulmonary embolism

   9. Participant has abnormal QT interval corrected by Fridericia's formula (> 450 msec for
   male participants, > 470 msec for female participants, or > 480 msec for participants
   with bundle branch block) after electrolytes have been corrected at screening.

10. Participant is using concomitant medications that are known to prolong the QT/QTcF
   interval including Class Ia (e.g., quinidine, procainamide, disopromide) and Class III
   (e.g., dofetilide, ibutilide, sotalol) antiarrhythmics at the time of informed
   consent. Non-antiarrhythmic medications which may prolong the QT/QTcF interval are
   allowed provided the participant does not have additional risk factors for Torsades de
   Pointes (TdP).

11. Participant has congenital long QT syndrome.

12. Participant has a history of additional risk factors for Torsades de pointes (TdP)
   (e.g., heart failure, hypokalemia, family history of long QT syndrome.

13. Participant has current or chronic history of liver disease or known hepatic or
   biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).

14. Participant is currently enrolled or was enrolled within 28 days of first dose of
   study treatment in another clinical study with any investigational drug or device.

Intervention(s):

drug: Nirogacestat

procedure: Cryoablation

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Behnaz Agahian
650-498-0623

New Trial Alerts

Receive email alerts when trials open to patients.